Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | NOS3 | P29474 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919175 | 1.00 | MIF (0.59) | MIFNOS3NOS2LMNAHKDC1 | |
| SCHEMBL7115158 | 0.83 | MIF (0.61) | MIFNOS3NOS2LMNAHKDC1 | |
| SCHEMBL7097516 | 0.83 | MIF (0.61) | MIFNOS3NOS2LMNAHKDC1 | |
| SCHEMBL919486 | 0.82 | MIF (0.46) | MIFNOS3NOS2LMNATAAR1 | |
| SCHEMBL13594117 | 0.79 | MIF (0.57) | MIFNOS3NOS2LMNAHKDC1 | |
| SCHEMBL9921621 | 0.79 | MIF (0.57) | MIFNOS3NOS2LMNAHKDC1 | |
| SCHEMBL4199092 | 0.79 | TRPA1 (0.45) | MIFNOS3NOS2LMNATRPA1 | |
| SCHEMBL920068 | 0.79 | MIF (0.43) | MIFNOS3NOS2LMNAHTR2A | |
| SCHEMBL8634299 | 0.77 | SIGMAR1 (0.46) | MIFTRPA1TAAR1HTR2AHRH1 | |
| SCHEMBL11174381 | 0.76 | HRH1 (0.56) | MIFNOS3NOS2TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358709-B1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DU PONT (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8618137-B2 | Fungicidal heterocyclic compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| US-8586611-B2 | Fungicidal carboxamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1948649-B1 | FUNGICIDAL CARBOXAMIDES | DU PONT (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8420673-B2 | Fungicidal amides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110269712-A1 | Fungicidal Carboxamides | BISAHA JOHN JOSEPH | 2011-11-03 | — | — | US | disclosed |
| US-20110224258-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20100004288-A1 | FUNGICIDAL AMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269712-A1 | Fungicidal Carboxamides | NAT1, PFAS, CHRM1 | MIF 3529/4885NOS3 811/4885NOS2 935/4885 |
| US-20110224258-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | NOX1, XDH, CBR1 | MIF 4006/4885NOS3 105/4885NOS2 240/4885 |
| US-20100004288-A1 | FUNGICIDAL AMIDES | NAT1, NOX1, Q6ZSR9 | MIF 3760/4885NOS3 60/4885NOS2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.